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1334Objective: The myocardial protective effect of remote ischemic preconditioning has been demonstrated in hetero-
geneous groups of patients undergoing cardiac surgery. No studies have examined this technique in neonates. The
present studywasperformed to examine the remote ischemic preconditioning efficacy in this high-riskpatient group.
Methods: A preliminary, randomized, controlled trial was conducted to investigate whether remote ischemic
preconditioning in cyanosed neonates undergoing cardiac surgery confers protection against cardiopulmonary
bypass. Two groups of neonates undergoing cardiac surgery were recruited for the present study: patients with
transposition of the great arteries undergoing the arterial switch procedure and patients with hypoplastic left
heart syndrome undergoing the Norwood procedure. The subjects were randomized to the remote ischemic pre-
conditioning or sham control groups. Remote ischemic preconditioning was induced by four 5-minute cycles of
lower limb ischemia and reperfusion using a blood pressure cuff. Troponin I and the biomarkers for renal and
cerebral injury were measured pre- and postoperatively.
Results:A total of 39 neonates were recruited—20 with transposition of the great arteries and 19 with hypoplas-
tic left heart syndrome. Of the 39 neonates, 20 were randomized to remote ischemic preconditioning and 19 to
the sham control group. The baseline demographics appeared similar between the randomized groups. The car-
diopulmonary bypass and crossclamp times were not significantly different between the 2 groups. The troponin I
levels were not significantly different at 6 hours after cardiopulmonary bypass nor were the postoperative ino-
trope requirements. Markers of renal (neutrophil gelatinase-associated lipocalin) and cerebral injury (S100b,
neuron-specific enolase) were not significantly different between the 2 groups.
Conclusions: Our data suggest that remote ischemic preconditioning in hypoxic neonates undergoing cardio-
pulmonary bypass surgery does not provide myocardial, renal, or neuronal protection. Additional studies are
needed to examine the relationships among developmental age, hypoxia, and the molecular mechanisms of
ischemic preconditioning. (J Thorac Cardiovasc Surg 2013;146:1334-40)Earn CME credits at
http://cme.ctsnetjournals.org
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Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
HLHS ¼ hypoplastic left heart syndrome
IPC ¼ ischemic preconditioning
IR ¼ ischemia–reperfusion
NGAL ¼ neutrophil gelatinase-associated lipocalin
NSE ¼ neuron-specific enolase
RIPC ¼ remote ischemic preconditioning
TGA ¼ transposition of the great arteries
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Thus, significant interest remains in therapies that can min-
imize organ injury in this setting. Extensive work has exam-
ined the innate protective mechanism of ischemic
preconditioning (IPC), initially described in 1986.3 The de-
livery of a direct IPC stimulus to the organ of interest has
been demonstrated to reduce IR injury in the heart and other
organs across a wide range of studied species. However, it
was not until 1993 that the paradigm of a remote stimulus
to induce protection of a distant organ was first described.4
In 2006, we reported our findings of the first randomized
control trial in humans of the protective effect of remote
IPC (RIPC) in children undergoing cardiac surgery for con-
genital heart defects.5 In that study, we demonstrated myo-
cardial protection with lower levels of postoperative
troponin I release and also improved ventricular function
in those children receiving RIPC.
Because that previous studywas limited by patient hetero-
geneity owing to the diverse congenital heart defects and
a wide age range, the aim of the present randomized con-
trolled trial was to examine RIPC in a more homogeneous
group of children undergoing cardiac surgery. Neonates
with either transposition of the great arteries (TGA) or hypo-
plastic left heart syndrome (HLHS) were selected because
the arterial switch operation and the stage I Norwood proce-
dure are lengthy, but relatively uniform, surgical procedures
performed at a point of organ immaturity when the reduction
of organ injury could confer its greatest clinical benefit.METHODS
Neonatal patients (<28 days old) undergoing the arterial switch proce-
dure for TGA, or the Norwood stage 1 procedure with a modified Blalock-
Taussig shunt for HLHS at the Royal Children’s Hospital (Melbourne,
Victoria, Australia) were identified. Patients with chromosomal defects, as-
sociated congenital lung malformations, and hematologic disorders were
excluded. Also, children outside the neonatal period at surgical repair
were excluded. Patients requiring intracardiac surgery involving direct
trauma to the ventricular myocardium, such as ventricular septal defect clo-
sure or a right ventricle to pulmonary artery conduit, were excluded to
avoid confounding the assessment of myocardial injury by measurement
of the plasma levels of troponin I.
The patients’ parents or guardians provided informed consent before en-
rollment. After recruitment, the subjects were randomized to either theThe Journal of Thoracic and CarRIPC or the sham control group. The randomization schedule was gener-
ated by the Clinical Biostatistics and Epidemiology Unit (Murdoch
Children’s Research Institute, Melbourne, Victoria, Australia). Randomi-
zation was by block and stratified by the 2 diagnostic groups (HLHS and
TGA) with a 1:1 ratio. Only the researchers were aware of the randomiza-
tion, and the staff providing clinical carewas unaware of the randomization
and group allocations.
The Royal Children’s Hospital human research ethics committee ap-
proved the study protocol. The study was registered with the Australia
New Zealand Clinical Trials Registry (ACTRN12607000004460).
Anesthesia and CPB Protocol
The anesthetic protocol was as follows. For infants with intravenous
access, induction was with intravenous fentanyl (10-50 mg/kg) and pan-
curonium (0.2 mg/kg). For those without intravenous access, induction
was with inhalational agents (nitric oxide or sevoflurane 3%) and topical
lidocaine (4 mg/kg) to the vocal cords before intubation. All subjects
received methylprednisolone (25 mg/kg) and cephazolin (50 mg/kg and
then 20 mg/kg every 3 hours). Aprotonin (50,000 kallikrein inhibition
units/kg loading dose and then 10,000 kallikrein inhibition units/kg/hr
plus 10,000 kallikrein inhibition units/100 mL pump prime) was used
during the initial period of the study before it became unavailable;
thereafter, tranexamic acid was used (100 mg/kg loading dose and then
10 mg/kg/hr).
Anesthesia was maintained with fentanyl boluses of 10 to 20 mg/kg as
required to cover the incision, sternotomy, and post-CPB phases, morphine
(0.2 to 0.5 mg/kg in the pump prime) and pancuronium (0.1-0.2 mg/kg and
0.2 mg/100 mL of pump prime). Isoflurane (2%) was titrated as required,
including during CPB.
CPB was established by direct superior vena cava, inferior vena cava,
and ascending aortic cannulation. Our standard circuit was primed using
plasmalyte 148 with added heparin, calcium, bicarbonate, and 20% albu-
min. Fresh packed red blood cells less than 3 days old that were leukocyte
depleted and irradiated were added, followed by hemofiltration of the
prime solution to a reservoir volume of 250 mL.
In our unit, all patients with HLHS undergoing the Norwood procedure
were cooled to 26C during CPB, with selective cerebral low flow perfu-
sion used. The adequacy of cerebral oxygenation was assessed using
near infrared spectroscopy. Patients with TGA undergoing arterial switch
operation were cooled to 32C during CPB.
Modified ultrafiltration was performed according to standard bypass
protocols at the Royal Children’s Hospital. The duration of CPB and aortic
crossclamp time and the intraoperative opiate dose were recorded.
RIPC Protocol
After induction of general anesthesia and insertion of arterial moni-
toring and central venous lines, the RIPC protocol was performed. Pre-
conditioning was induced by four 5-minute cycles of lower limb
ischemia and 5 minutes of reperfusion using a blood pressure cuff in-
flated around the thigh to a pressure 15 mm Hg greater than the moni-
tored systolic arterial pressure. The control patients underwent sham
placement of the blood pressure cuff around the thigh without inflation.
The clinicians caring for the patients were screened from the precondi-
tioning procedure.
Outcome Measures
The primary outcome measure was the troponin I level at 6 hours after
CPB as a marker of myocardial injury. The secondary outcome measures
were the troponin levels at 3, 12, and 24 hours after CPB and the neutrophil
gelatinase-associated lipocalin (NGAL), neuron-specific enolase (NSE),
and S100B levels at 3, 6, 12, and 24 hours after CPB. The cardiovascular
status, lung function, and postoperative inotrope requirements were also as-
sessed at 3, 6, 12, and 24 hours after CPB.diovascular Surgery c Volume 146, Number 6 1335
TABLE 1. Preoperative characteristics of treatment and sham control
groups
Characteristic Treatment group (n ¼ 20) Control group (n ¼ 19)
Age at surgery (d) 8.1  5.2 5.5  4.2
Weight (kg) 3.5  0.577 3.4  0.449
BSA (m2) 0.21  0.022 0.21  0.016
Troponin I (mg/L) 0.061  0.081 0.041  0.035
S100b (pg/mL) 203.0  48.4 226.2  117.3
NSE (mg/L) 149.8  75.5 96.7  49.5
NGAL (ng/mL) 59.2  38.6 46.1  38.3
TGA 11 (55) 9 (51)
HLHS 9 (45) 10 (49)
Data presented as mean  standard deviation or n (%). BSA, Body surface area;
NSE, neuron-specific enolase; NGAL, neutrophil gelatinase-associated lipocalin;
TGA, transposition of great arteries; HLHS, hypoplastic left heart syndrome.
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All blood samples were collected from the arterial monitoring catheter.
The samples were collected at baseline immediately before surgery and
again at 3, 6, 12, and 24 hours after surgery. The samples were collected,
centrifuged, and frozen at 70C for subsequent analysis. The analyses
of the samples were performed in triplicate and blinded to treatment group.
The plasma troponin I levels were measured as a marker of myocardial in-
jury using the Abbott AxSYMTroponin-I immunoassay (Abbott Laborato-
ries, Abbott Park, Ill). Assays of the markers of cerebral injury (S100b,
NSE) and renal injury (NGAL) were also performed using sandwich
enzyme-linked immunosorbent assay microtiter plate-based spectrophoto-
metric procedures. For NGAL, previously described methods were used,6
with polyclonal human NGAL and avidin-conjugated horseradish peroxi-
dase antibodies (catalog no. KA0043 V.03; Abnova, Taipei City, Taiwan).
S100b was similarly determined using monoclonal antibody for human
S100b recognition (Abnova, catalog no. KA0037). Human NSE (g-subunit
recognition) was quantitatively determined for the biotinylated antibody-
NSE-chromogen complex using the general method of Paus and Nustad7
(catalog no. 0050; Alpha Diagnostic International, San Antonio, Tex).
The total protein levels were determined using the bicinchoninic acid pro-
tein assay (Sigma-Aldrich, St Louis, Mo).
Postoperative Assessment
The patients’ postoperative recovery in the intensive care unit was as-
sessed at the same points as for blood sampling (3, 6, 12, and 24 hours after
CPB) and included documentation of inotropic support, ventilatory sup-
port, urine output, and arterial lactate levels. The postoperative opiate
dose, total duration of ventilation, and length of intensive care unit stay
were also documented. The oxygenation index and alveolar-arterial
gradient were calculated from the ventilatory parameters: (oxygenation
index ¼ fraction of inspired oxygen 3 mean arterial pressure/arterial par-
tial pressure of oxygen; alveolar-arterial gradient ¼ alveolar partial pres-
sure in oxygen  arterial partial pressure in oxygen). The vasoactive
inotrope score was calculated according to the previously described for-
mula8: vasoactive inotrope score ¼ dopamine dose (mg/kg/
min) þ dobutamine dose (mg/kg/min) þ 100 3 adrenaline dose (mg/kg/
min) þ 100 3 noradrenaline dose (mg/kg/min) þ 10 3 milrinone dose
(mg/kg/min). The total opiate requirements were determined as the sum
of the intraoperative and postoperative opioid doses. The doses of fentanyl
were converted into morphine equivalents per kilogram body weight using
a relative potency of fentanyl to morphine of 100:1.9
Sample Size and Statistical Analysis
A paucity of data was available for this patient population to enable an
accurate sample size calculation. The intention was to use the data from the
present preliminary study to determine the future sample size calculations.
The difference between the treatment and control groups was estimated
using linear regression analysis, with adjustment for the stratification factor
(TGA or HLHS).
In each of the 2 diagnostic groups, the difference between the treatment
and control group was estimated using t tests.
Differences between the treatment groups were investigated at 3, 6, 12,
and 24 hours after surgery. For the variables measured at several points af-
ter surgery, a summary measure, the area under the curve, was also calcu-
lated, as an alternative outcome measure.
Statistical analysis was performed using Stata, version 11 (StataCorp
2011, College Station, Tex).RESULTS
Neonates
A total of 39 neonates were recruited from January 2008
to January 2011, 20 with TGA and 19 with HLHS. In the1336 The Journal of Thoracic and Cardiovascular SurTGA group, 11 were randomized to RIPC and 9 to the
sham control group, and in the HLHS group, 9 were ran-
domized to RIPC and 10 to the sham control group. All sub-
jects received the intervention according to their allocation.
The preoperative characteristics between the RIPC and
sham groups were similar (Table 1). No local adverse events
or changes to cardiovascular stability occurred in relation-
ship to the preconditioning stimulus in either group.
The mean age at surgery was 8.1  5.2 days in the RIPC
group and 5.5 4.2 days in the control group. The duration
of CPB and the crossclamp time appeared similar between
the 2 groups (Table 2). The mean interval from the comple-
tion of the RIPC protocol to the beginning of CPB was 80
minutes (range, 50-120 minutes). Two subjects received
aprotinin during surgery, with the rest receiving tranexamic
acid.
No deaths occurred in the perioperative period (30 days)
in either group, and all subjects were successfully dis-
charged from the hospital.
Myocardial Function and Injury
In the total cohort, the mean troponin level at 6 hours af-
ter CPB was 11.4 mg/L in the RIPC group and 10.6 mg/L in
the control group, with no differences evident (Table 3 and
Figure 1). Similarly, no evidence was found of a difference
at the other measurement points analyzed nor with
a 24-hour area under the curve analysis, although the confi-
dence intervals were wide. Other indirect markers of myo-
cardial function and cardiac output, including inotrope
scores, urine output, and serum lactate levels, were not
statistically significantly different between the 2 groups
(Table 4).
Lung Function
No evidence was found of a difference in the oxygenation
index or alveolar-arterial oxygen difference between the 2
groups (Table 4). No statistically significant difference
was found in the duration of mechanical ventilation be-
tween the 2 groups (HLHS: RIPC, 126  31 hours, vsgery c December 2013
TABLE 2. Intraoperative data
Variable Treatment group mean Control group mean
Mean difference
(control minus treatment)*
95% CI for
mean difference* P value Patients (n)
Total cohort
CPB time (min) 173.9 185.4 12.0 12.5, 36.6 .33 39
Crossclamp time (min) 95.3 94.4 1.7 13.5, 16.9 .82 39
TGA
CPB time (min) 172.6 194.1 21.5 1.7, 44.7 .07 20
Crossclamp time (min) 109.3 114.4 5.2 7.4, 17.7 .40 20
HLHS
CPB time (min) 175.4 177.6 2.2 44.4, 48.7 .92 19
Crossclamp time (min) 78.3 76.4 1.9 31.8, 28.0 .89 19
CI, Confidence interval; CPB, cardiopulmonary bypass; TGA, transposition of great arteries; HLHS, hypoplastic left heart syndrome. *Adjusted for stratification factor
(TGA vs HLHS).
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hours, vs control, 66  56 hours; P ¼ .44).
Other Markers of Renal and Cerebral Injury
No evidence was found of a difference in the serum levels
of the markers of renal injury (NGAL) or cerebral injury
(NSE and S100b) between the 2 groups (Table 4).
Peritoneal dialysis was needed in 35% of the treatment
group and 42% of the control group (P ¼ .65, chi-square
test). No significant neurologic events were reported in
either group; however, formal neurologic assessments
were not performed.
Intraoperative and Postoperative Opiates
No evidence was found of a difference in the intraopera-
tive and postoperative opiate dosage (quantified in mor-
phine equivalents) between the 2 groups. Intraoperatively,
the dosage for the control group was a mean of
7.36  2.95 mg/kg, and for the RIPC group, it was
8.19  3.57 mg/kg (P ¼ .44). Postoperatively, the dosage
for the control group was a mean of 1.64  1.03 mg/kg,
and for the RIPC group, it was 1.8  1.1 mg/kg
(P ¼ .65). No correlation was found between the intraoper-
ative opiate dose and the postoperative troponin I levels.
DISCUSSION
Since thefirst clinical human study demonstrating the ben-
eficial effects of RIPC on myocardial protection in childrenTABLE 3. Primary outcome (all patients, adjusted for diagnosis
group)
Variable
Troponin at 6 hr (mg/L)
Unadjusted
Adjusted for
preoperative troponin
Mean difference (control minus
treatment)
0.29 0.18
95% CI for mean difference 3.3, 2.7 3.3, 2.9
P value .85 .91
Patients (n) 38 38
CI, Confidence interval.
The Journal of Thoracic and Carundergoing cardiac surgery for congenital heart disease,5 nu-
merous human studies have applied this technique, although
predominantly in adults. In a large randomized trial, RIPC
was shown to reduce myocardial injury in patients undergo-
ing coronary artery bypass grafting and receiving cold blood
cardioplegia, with a 42% reduction in troponin release
(AUC 72 hours mean difference, 13.37 mg/L.72 hours;
95% confidence interval, 2.41-24.33,P¼ .019).10 Addition-
ally, a systematic review and meta-analysis of pooled data
from 184 subjects demonstrated a statistically significant
benefit of RIPC compared with a control group for
a reduction in the biomarkers of myocardial injury.11
A paucity of studies, however, of children with congeni-
tal heart disease is available. One study of 60 infants under-
going surgical repair of ventricular septal defects12 also
demonstrated myocardial and pulmonary protection as a re-
sult of RIPC administered at 24 hours and 1 hour before
CPB. The subjects randomized to preconditioning had
lower troponin levels at 4 hours after CPB (RIPC,
2.1  0.32 mg/L vs control, 2.41  0.32 mg/L; P< .05).
These children were older than our study population, withFIGURE 1. Troponin I levels at baseline and 3, 6, 12, and 24 hours after
cardiopulmonary bypass. RIPC, Remote ischemic preconditioning.
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TABLE 4. Secondary outcomes
Variable Treatment group mean Control group mean
Mean difference
(control minus treatment)*
95% CI for
mean difference* Patients (n)
Troponin (mg/L)
At 3 h 12.2 13.7 1.9 1.8, 5.6 38
At 12 h 8.9 8.4 0.2 2.5, 2.2 39
At 24 h 5.6 4.8 0.4 1.8, 0.9 37
Urine output (mL/kg/h)
At 3 h 2.1 2.2 0.1 1.3, 1.5 39
At 6 h 1.2 1.5 0.4 0.5, 1.3 39
At 12 h 1.0 1.1 0.1 0.7, 0.9 39
Urine output (mL) 24 h 5.8 5.2 0.4 4.2, 3.3 39
Lactate
At 3 h 3.0 3.1 0.1 0.9, 1.0 38
At 6 h 2.4 2.7 0.2 0.8, 1.1 39
At 12 h 2.3 2.6 0.2 0.7, 1.1 39
At 24 h 1.8 2.2 0.3 0.1, 0.7 39
Inotrope score
At 3 h 6.2 9.0 2.5 1.4, 6.5 39
At 6 h 6.8 9.4 2.6 0.7, 5.9 39
At 12 h 7.6 9.7 2.2 1.5, 5.9 39
At 24 h 6.8 8.9 2.2 0.9, 5.4 39
Alveolar-arterial difference
At 3 h 169.8 150.0 21.6 83.5, 40.4 39
At 6 h 151.7 146.0 5.8 58.4, 46.7 39
At 12 h 127.5 109.8 16.9 61.1, 27.3 39
At 24 h 98.0 92.1 5.7 47.2, 35.7 39
OI
At 3 h 7.1 8.6 1.0 2.5, 4.4 39
At 6 h 6.1 6.9 0.5 1.7, 2.7 39
At 12 h 5.7 5.3 0.7 2.5, 1.1 39
At 24 h 4.7 4.8 0.2 1.5, 1.2 39
S100b (pg/mL) at24 h 173.3 132.3 37.8 111.2, 35.7 30
NSE (mg/L) at 24 h 107.2 111.0 4.2 31.6, 40.1 30
NGAL (ng/mL)
At 3 h 57.7 59.0 0.8 22.6, 21.0 29
At 6 h 56.8 54.3 6.4 25.9, 13.1 27
At 12 h 63.2 62.3 2.5 22.6, 17.5 34
At 24 h 77.5 60.0 19.4 47.8, 8.9 29
CI, Confidence interval; OI, oxygenation index; NSE, neuron-specific enolase; NGAL, neutrophil gelatinase-associated lipocalin; TGA, transposition of greater arteries; HLHS,
hypoplastic left heart syndrome. *Adjusted for stratification factor (TGA or HLHS).
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that study had normal oxygen saturation at rest. Pavione and
colleagues13 evaluated the late effects of RIPC in children
undergoing cardiac surgery by administering the RIPC
stimulus 24 hours before CPB. These children were also
older than our study population (age range, 1.4-21.1
months) and included a heterogeneous group of cardiac di-
agnoses. Although no significant difference was found in
the troponin levels, inflammatory markers, or clinical out-
comes between the RIPC and control groups, the N-termi-
nal pro-B-type natriuretic peptide levels were lower in the
RIPC group. The investigators suggested that a myocardial
protective effect might have been present that was not
clinically significant. That study, however, had a small sam-
ple size (22 children in total) and might have been1338 The Journal of Thoracic and Cardiovascular Surunderpowered to detect a difference in the troponin levels
and clinical parameters.
Organ Injury
In common with many other studies, we chose troponin I
as the primary marker of myocardial injury. No evidence
was seen of a difference between the RIPC and control
groups in troponin I levels. Nor was evidence found of dif-
ferences in the indexes of systemic perfusion or inotrope re-
quirement, suggesting no difference in the degree of
myocardial dysfunction between the groups. Importantly,
no evidence was found that the RIPC stimulus was harmful
to myocardial function.
There are several potential reasons why we were unable
to detect any difference in myocardial injury in ourgery c December 2013
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relative to birth, organ immaturity, and tissue hypoxia. It has
previously been reported that the infant heart exhibits high
levels of endogenous methionine-enkephalin, and. in partic-
ular, an inverse correlation exists between the arterial oxy-
gen saturation and myocardial methionine-enkephalin
content in children undergoing tetralogy of Fallot repair.14
Preconditioning has been demonstrated to be protective in
mature myocardium in both animal and human studies;
however, doubts have been raised regarding the efficacy
of preconditioning on the newborn and immature myocar-
dium, with conflicting data from animal studies. Bin and
colleagues15 showed no protection against IR injury with
preconditioning in a juvenile rabbit model (aged 14-21
days). In a rat model, Awad and colleagues16 demonstrated
that protection against IR injury was provided by precondi-
tioning after 7 days of age but not before. This finding con-
flicts with the data from Liu and colleagues, who
demonstrated a protective effect in immature rabbit hearts
(aged 4-7 days).17 Baker and colleagues18 also showed
that a single cycle of 5 minutes of direct ischemia and 10
minutes of reperfusion conferred protection from global is-
chemia in the normoxic immature rabbit heart (aged 7-10
days). These discrepancies in findings could be ascribed
to the different animal species, models, endogenous opioid
peptide levels, and variable rates of intracellular signal
transduction system maturation.
Chronic myocardial hypoxia has been demonstrated in
mature animal models to improve tolerance to reperfu-
sion–reperfusion injury.19 Furthermore, Tajima and col-
leagues20 demonstrated that chronic hypoxia increased
myocardial tolerance to ischemia in 3-week-old rats and
that acute IPC increased this tolerance further. However,
the molecular mechanisms responsible for the myocardial
protection conferred by chronic hypoxia remain poorly
understood. Possible contributory mechanisms for this re-
sistance include elevated levels of hypoxia-inducible fac-
tor-1a,21 and alterations in nitric oxide synthase.
There is some suggestion from animal data that chronic
hypoxia also confers protection in immature myocardium;
however, the cumulative effect of chronic hypoxia and pre-
conditioning has been questioned. In the study by Baker and
colleagues,18 a separate group of animals were raised from
birth in hypoxic conditions and studied at a similar age
(7-10 days). The same protocol of IPC in these hypoxic an-
imals had no effect on resistance to an ischemic insult. In-
creasing the number of cycles of IPC also did not have
any beneficial effect. The hearts of the hypoxic control an-
imals tolerated global ischemia better than did the normoxic
controls, suggesting that chronic hypoxia in itself conferred
protection in these immature hearts.
The possibility of potentially detrimental effects of IPC
on ventricular function after global IR injury has been raised
in a recent animal study.22 However, our data did notThe Journal of Thoracic and Carsupport these findings and did not show any difference in
the clinical course or surrogate markers of ventricular func-
tion. It must be highlighted, however, that our patients were
all cyanosed.
The ability of the hypoxic and immature myocardium to
withstand ischemia is of great importance, because many
children with complex cyanotic heart malformations un-
dergo cardiac surgery in the neonatal period. The findings
from animal studies have suggested that chronically hyp-
oxic immature hearts could be protected by adaptation to
hypoxia; however, no additional protection is provided by
IPC. It is possible that IPC signaling pathways might not
be fully mature in the developing neonate. Additional stud-
ies are clearly needed to examine the relationship among
myocardial maturity, hypoxia, and IPC.
Injury to Other Organs
No evidence was found of a difference between the
markers of either neuronal or renal injury between the
RIPC and control groups. This might have been because
of a lack of effect or because subtle injuries were not able
to be detected using the assays. Because ours was an acute
study, the potential role in protection against long-term neu-
ropsychological sequelae was not assessed.
Animal studies of cerebral injury have demonstrated the
protective effect of preconditioning against injury from hy-
pothermic circulatory arrest.23,24 Jensen and colleagues23
used a surviving animal model and demonstrated protection
according to biochemical, functional, and histologic find-
ings. However, conflicting data remain regarding the opti-
mal time of preconditioning for cerebral protection, with
our own experimental study of rats demonstrating a lack
of cerebral protection.24,25 The role of preconditioning in
cerebral protection of the immature brain is unknown, and
no other human studies to date have examined the effects
of RIPC on neurologic injury after cardiac surgery.
Acute kidney injury after cardiac surgery in children is
common, with some studies reporting that up to 11.5% of
children require dialysis.26 Some evidence has shown that
RIPC might protect renal function from IR injury.27 How-
ever, a recent randomized controlled study of RIPC28 of
105 children undergoing cardiac surgery was unable to
demonstrate renal protection. A difference was found in
the incidence of acute kidney injury (41% in RIPC group
and 67% in the control group; P ¼ .04) in children older
than 12 months that might also reflect a maturational re-
sponse to preconditioning. That study supports our findings
and perhaps also reflects the relatively low sensitivity and
specificity of the available biomarkers.
Study Limitations
The lack of a statistically significant difference be-
tween the 2 groups might be primarily attributed to an insuf-
ficient sample size and the study being underpowered.diovascular Surgery c Volume 146, Number 6 1339
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DHowever, similar size studies of other patient populations,
including children, have demonstrated clinical effects.5,12
Additionally, no evidence was found of a clinically
detectable difference between the 2 groups.
The preconditioning properties of inhalational anes-
thetics and opiates have been well described; however,
these factors and other potentially confounding variables
were minimized by using standardized anesthetic and per-
fusion protocols.CONCLUSIONS
Our data suggest that IPC in hypoxic neonates does not
provide cardioprotection, nor protection against renal or ce-
rebral injury in newborns undergoing cardiac surgery for
cyanotic heart disease. It remains unclear whether the use
of blood cardioplegia, opiates, and the intrinsic organ prop-
erties unique to these neonatal patients might have masked
or negated any additional protective benefit of RIPC. Be-
cause it would clearly be desirable to maximize organ pro-
tection in this vulnerable group of patients and minimize
long-term morbidity, additional studies are required to ex-
amine the relationship among myocardial development,
age, hypoxia, and IPC.References
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